Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Acute Myeloid Leukaemia: Update Bulletin [August 2017]

Product Code:
596200742
Publication Date:
August 2017
Format:
PDF
Price:
€975

This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) space. Topics covered include expert opinions on; Seattle Genetics reporting the termination of the Phase III CASCADE study with its anti-CD33 agent vadastuximab talirine (SGN-CD33A) as a front-line approach in older patients with AML; the FDA’s Oncologic Drugs Advisory Committee (ODAC) granting a positive review of Pfizer’s anti-CD33 antibody-drug conjugate Mylotarg (gemtuzumab ozogamicin) in patients with previously untreated, de novo AML; and final Phase I/II results from the CHRYSALIS study with Astellas’ FLT3/AXL kinase inhibitor gilteritinib (ASP2215) which were published recently in the Lancet Oncology.

Business Questions:

  • How do KOLs view the termination of the Phase III CASCADE trial with Seattle Genetics’ vadastuximab talirine?
  • What is the future potential for vadastuximab talirine in AML?
  • What are KOL reactions to the ODAC’s positive vote to recommend the approval of Pfizer’s Mylotarg in previously untreated, de novo AML patients?
  • To what extent is the ALFA-0701 trial considered compelling evidence in support of Mylotarg?
  • What are KOL opinions on the proposed lower dosing of Mylotarg?
  • To what extent are KOLs impressed by the results from the CHRYSALIS study of Astellas’ gilteritinib?
  • Are KOLs concerned by the adverse event risk in the CHRYSALIS trial?
  • If gilteritinib were to be approved in AML, in which patient types would KOLs consider use?



customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved